Multiple Myeloma

EntreMed presents data on combination of Panzem and Velcade in multiple myeloma

Published in Biotech Business Week, January 8th, 2007

EntreMed, Inc. (ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the results of in vitro and in vivo preclinical studies showing a treatment benefit in multiple myeloma with the combination of Panzem (2- methoxyestradiol or 2ME2) and Velcade (bortezomib) over either agent used alone.

The results from these studies, conducted by EntreMed researchers, were presented at the 48th Annual Meeting of the American Society of Hematology in Orlando, Florida.

Panzem is currently being evaluated in Phase 1 and Phase 2 oncology clinical trials, including multiple myeloma. In...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2007-01-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry